# Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol

> **NCT06764238** · PHASE2,PHASE3 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 1800 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia ALL
- Childhood Leukemia, Acute Lymphoblastic
- B Cell Acute Lymphoblastic Leukemia (B-ALL)

## Interventions

- **DRUG:** Blinatumomab (Group A)
- **DRUG:** Venetoclax (nonRand Group)
- **DRUG:** Blinatumomab (Group B)

## Key facts

- **NCT ID:** NCT06764238
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-03
- **Primary completion:** 2029-12-31
- **Final completion:** 2031-06
- **Target enrollment:** 1800 (ESTIMATED)
- **Last updated:** 2025-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06764238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06764238, "Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06764238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*